Side-by-side comparison of AI visibility scores, market position, and capabilities
NYSE-listed accessible beauty brand with $1B+ revenue offering vegan makeup at $5-20 drugstore prices; TikTok-viral "dupe" strategy competing with NYX and prestige brands for Gen Z consumers.
e.l.f. Cosmetics is an accessible luxury beauty brand producing makeup, skincare, and beauty tools at drugstore price points — offering products like primers, foundations, eyeshadow palettes, lip glosses, and SPF moisturizers that are entirely vegan and cruelty-free, at price points of $5-20 that undercut premium brands by 80-90%. Founded in 2004 in Oakland, California by Joseph Shamah and Scott Vincent Borba, e.l.f. is publicly traded on NYSE (NYSE: ELF) and has grown to approximately $1 billion in annual net sales, becoming one of the fastest-growing beauty brands in the US.\n\ne.l.f.'s product development strategy involves "duping" high-end makeup products at a fraction of the cost — the e.l.f. Putty Primer ($10) is a frequent comparison to Tatcha Silk Canvas Primer ($52), the Halo Glow Liquid Filter ($14) competes with Charlotte Tilbury Hollywood Flawless Filter ($46). This dupe culture has made e.l.f. a social media phenomenon, particularly on TikTok where product comparisons and "get the look" content drives viral awareness. The brand's 100% vegan and cruelty-free credentials resonate strongly with Gen Z consumers.\n\nIn 2025, e.l.f. is one of the few beauty brands that has consistently taken market share from both mass and prestige competitors — its "eyes, lips, face" brand promise and the value proposition of luxury quality at drugstore prices has driven growth even as overall beauty market growth moderates. e.l.f. competes with NYX (L'Oréal), Wet n Wild, and Maybelline in accessible makeup, and with Rare Beauty, Too Faced, and Urban Decay in the prestige-adjacent segment. The 2025 strategy focuses on skincare expansion (a higher-growth category with better margins than color cosmetics), international expansion (UK, Canada, and European markets where brand awareness is growing), and maintaining the digital-native marketing approach that has built its Gen Z audience.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.